Clonazepam (Rivotril)
Clonazepam risk profile, scheduling, and guidance for claims professionals and care workers . Also known as Rivotril, Paxam 0.5, Paxam 2.
Clonazepam (brand names: Rivotril, Paxam 0.5, Paxam 2) is classified as Moderate risk (3 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. Long-acting benzodiazepine with high dependency potential and respiratory depression risk.
Key Takeaways
- TGA Schedule: S4 in Australia
- Risk level: Moderate (3 points)
- CNS depressant: May cause sedation, impair driving, and affect work capacity
- Respiratory depression risk: Requires monitoring, especially with other CNS depressants
- Recommended maximum duration: 28 days
- SIRA reportable: Flagged for NSW workers compensation reporting
- PBS listed: Subsidised under the Australian Pharmaceutical Benefits Scheme
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S4 | PBS listed |
Risk Profile
Long-acting benzodiazepine with high dependency potential and respiratory depression risk.
Regulatory and Compliance Guidance
When Clonazepam appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.
Work capacity impact: As a CNS depressant, Clonazepam may impair driving, operating machinery, and cognitive function. Work capacity certificates should reflect any medication-related restrictions.
Australia TGA / PBS / State Schemes
Classified as S4 under the Therapeutic Goods Administration (TGA).
Listed on the Pharmaceutical Benefits Scheme (PBS) for subsidised prescribing.
Flagged as reportable under SIRA guidelines in NSW. Claims involving this medication may require additional reporting and clinical justification.
All Australian workers compensation schemes flag benzodiazepine use as high-risk, particularly when combined with opioids. Duration should be limited and tapering plans documented.
United States FDA / CDC / State WC
The CDC and FDA have issued joint warnings about the risks of concurrent benzodiazepine and opioid use. Workers compensation adjusters should flag this combination for clinical review.
Need to assess this medication across your caseload?
Run a full risk assessment including Clonazepam interactions and compliance checks.
AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.
No credit card required. No signup for your first 2 questions.
Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.